Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

A study finds that adjunctive use of GLP-1 receptor agonists before and after undergoing bariatric surgery produces greater ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Across these trials, 1.35% (279 of 20,598) of participants who received a GLP-1 RA had ≥1 episode of AFib reported as a serious adverse event, compared with 1.37% (282 of 20,608) of those who ...

The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...

There was a 132.6 percent increase in patients prescribed GLP-1 RAs between the last six months of 2022 and the last six months of 2023 (1.89 versus 4.41 patients per 1,000 patients).

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers (OACs ...

Originally developed for type 2 diabetes, GLP-1 RAs have gained significant traction globally for obesity treatment. With 32% of Australians classified as obese in 2022 and the cost of obesity ...